GE
GENB.O
—
NASDAQ
Biotechnology
Genb.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-737,0 %
ROE
-103,7 %
Net margin
-637,0 %
Debt / equity
0,04
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$13,14
Open
$13,59
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Generate Biomedicines Inc operates in the biotechnology sector within the Health Care industry, generating revenue from its biopharmaceutical activities.
Business. Generate Biomedicines Inc operates in the biotechnology sector within the Health Care industry, generating revenue from its biopharmaceutical activities.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Capital Research Global Investors
largest disclosed fund holder
Profitability→
-103,7 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to GENB.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Generate Biomedicines Inc operates in the biotechnology sector within the Health Care industry, generating revenue from its biopharmaceutical activities.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDGenerate Biomedicines maintains a conservative capital structure with minimal leverage, evidenced by a debt-to-equity ratio of 0.04 and long-term debt of $7.2 million against total equity of $195.9 million. The balance sheet is heavily weighted toward liquidity, with cash and equivalents totaling $121.7 million, providing a current ratio of 2.85. Despite this strong liquidity position, the company faces significant cash burn, with operating cash flow at -$200.6 million and free cash flow at -$259.7 million for the latest period.
Profitability metrics are deeply negative, reflecting the pre-commercial or early-stage nature of the business. Return on equity stands at -1.04, and return on assets is -0.62, indicating that the company is consuming capital rather than generating returns on its asset base. The company reported a net income loss of $203.2 million against revenue of $31.9 million, resulting in a substantial operating loss of $235.1 million. Without cohort median data for direct comparison, these figures are consistent with high-burn biotechnology firms in clinical development phases.
Segment and geographic revenue breakdowns are not provided in the available data, preventing an analysis of revenue concentration or regional exposure. The company’s total revenue of $31.9 million suggests a limited commercial footprint or reliance on milestone payments and licensing deals typical of early-stage biotechs.
Historical period data is absent, so a growth trajectory cannot be established from the provided inputs. The single-period snapshot shows a revenue figure of $31.9 million, but without prior periods, year-over-year growth or decline trends cannot be calculated.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary financial risk stems from the high cash burn rate relative to the cash balance; at the current free cash flow burn rate of $259.7 million, the existing cash reserves of $121.7 million would be depleted in less than six months if not for potential financing or operational changes.
Recent news observations indicate system-level reconciler events for the ticker GENB.O, noting zero analysis jobs for Generate Biomedicines Inc. No specific corporate filings, earnings transcripts, or strategic news events are present in the input data to provide further context on recent operational developments.
Key takeaways
- The company holds $121.7 million in cash but is burning through capital at a rapid rate, with free cash flow outflows of $259.7 million.
- Leverage is negligible with a debt-to-equity ratio of 0.04, reducing financial distress risk from debt obligations.
- Profitability is severely negative, with a net loss of $203.2 million and a return on equity of -1.04.
- Dilution risk is assessed as low, with no immediate flags for share issuance detected in the risk assessment.
- Classification confidence is low (0.20), suggesting potential ambiguity in the company's specific business activities or sector alignment.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$14,34
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$195.9M
Net cashⓘ
$114.4M
Current ratioⓘ
2.9
Debt / equityⓘ
0.0
ROAⓘ
-61.5%
ROEⓘ
-1.0%
Cash conversionⓘ
99.0%
CapEx / revenueⓘ
-11.0%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution6 analysts
Strong buy1
Buy5
Hold0
Sell0
Strong sell0
12-month price target$25,40 · Median $25,00
Low $22,00High $30,00
Operating income · consensus-273,2M USD
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$22,00
Mean$25,40
Median$25,00
High$30,00
Spot$14,34
+77.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-737,0 %Bottom quartile
Net Margin-637,0 %Below median
ROE-103,7 %Bottom quartile
Capex / Rev-11,0 %Bottom quartile
D/E0,04Below median
Cash Conv0,99Above P75
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 64 801 800 sh17 grants14 insiders
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 833 325conversion · 2026-03-02
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 1 388 876conversion · 2026-03-02
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 833 325conversion · 2026-03-02
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 1 666 651conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 1 388 876conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 555 550conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 1 944 427conversion · 2026-03-02
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 12 168 390conversion · 2026-03-02
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 11 202 248conversion · 2026-03-02
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 987 491conversion · 2026-03-02
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 987 491conversion · 2026-03-02
- Director · Series A Preferred Stock → Common StockDisposed 724 160conversion · 2026-03-02
- Director, Chief Executive Officer · Series A Preferred Stock → Common StockDisposed 658 327conversion · 2026-03-02
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 1 388 876conversion · 2026-03-02
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 833 325conversion · 2026-03-02
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 1 666 651conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 1 388 876conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 1 944 427conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 833 325conversion · 2026-03-02
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 12 168 390conversion · 2026-03-02
- Director, 10% owner · Series A Preferred Stock → Common StockDisposed 11 202 248conversion · 2026-03-02
- Director, 10% owner · Series B Preferred Stock → Common StockDisposed 555 550conversion · 2026-03-02
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 844 595 @ $16,00grant · 2026-02-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 29 561 @ $16,00grant · 2026-02-26
- Director · Stock Option (Right to Buy) → Common StockAcquired 29 561 @ $16,00grant · 2026-02-26
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Generate Biomedicines Inc Market data — financials · 2026-07-29
- reconciler_enqueue (reconciler) on GENB.O · 2026-07-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$50M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$53M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Leadership
- Gevorg GrigoryanCo-Founder, Chief Technology Officer
Insider activity
Net buying7 buys · 0 sellsnet $50,3M6 insiders · last 365d
- Director, Chief Executive Officer · Common StockBought 20 000 @ $12,00$240K · 2026-03-04
- President & CFO · Common StockBought 500 @ $16,00$8K · 2026-03-02
- President & CFO · Common StockBought 1 000 @ $16,00$16K · 2026-03-02
- Director, 10% owner · Common StockOther 12 723 940 · 2026-03-02
- Director, 10% owner · Common StockOther 13 702 224 · 2026-03-02
- Director, 10% owner · Common StockOther 987 491 · 2026-03-02
- Director, 10% owner · Common StockOther 2 777 752 · 2026-03-02
- Director, 10% owner · Common StockBought 1 562 500 @ $16,00$25,0M · 2026-03-02
- Director, Chief Executive Officer · Common StockOther 658 327 · 2026-03-02
- Director · Common StockOther 724 160 · 2026-03-02
- Director · Common StockBought 1 500 @ $16,00$24K · 2026-03-02
- Director, 10% owner · Common StockOther 12 723 940 · 2026-03-02
- Director, 10% owner · Common StockOther 13 702 224 · 2026-03-02
- Director, 10% owner · Common StockOther 987 491 · 2026-03-02
- Director, 10% owner · Common StockOther 2 777 752 · 2026-03-02
- Director, 10% owner · Common StockBought 1 562 500 @ $16,00$25,0M · 2026-03-02
- Chief People Officer · Common StockBought 300 @ $16,00$5K · 2026-03-02
Short positioning
7.0Mshares short+18.1% vs prior
9.38days to cover
83.1%short of daily vol
11.1Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
GENB.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Shares outstanding (annual): 33.12MUnknown
- Cash & equivalents (annual): USD 121.65MUnknown
- Total assets (annual): USD 330.18MUnknown
- Current assets (annual): USD 234.37MUnknown
- Total liabilities (annual): USD 141.55MUnknown
- Current liabilities (annual): USD 82.2MUnknown
- Shareholders' equity (annual): USD -615.97MUnknown
- Shareholders' equity (annual): USD -434.52MUnknown
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-03-04 00:00 UTCINSIDER39 insider transactions — 2026-03 · net buy $50.3M 22 derivative
2026-03-04 00:00 UTCINSIDER39 insider transactions — 2026-03 · net buy $50.3M 22 derivative
2026-03-04INSIDERNally Michael bought 20.0k sh — Director, Chief Executive Officer ~$240k
2026-03-02INSIDERAFEYAN NOUBAR transacted 12.72M sh — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR transacted 13.70M sh — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR transacted 987.5k sh — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR transacted 2.78M sh — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR bought 1.56M sh — Director, 10% owner ~$25.00M
2026-03-02INSIDERGrous Beth bought 300 sh — Chief People Officer ~$5k
2026-03-02INSIDERSilvers Jason bought 500 sh — President & CFO ~$8k
2026-03-02INSIDERSilvers Jason bought 1.0k sh — President & CFO ~$16k
2026-03-02INSIDERNally Michael transacted 658.3k sh — Director, Chief Executive Officer
2026-03-02INSIDERBancel Stephane transacted 724.2k sh — Director
2026-03-02INSIDERMendillo Jane L bought 1.5k sh — Director ~$24k
2026-03-02INSIDERAFEYAN NOUBAR disposed of 1.27M sh Series B Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 2.11M sh Series C Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 2.53M sh Series C Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 2.95M sh Series B Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 843.9k sh Series B Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 1.50M sh Series A Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 17.02M sh Series A Preferred Stock — Director, 10% owner
2026-03-02INSIDERAFEYAN NOUBAR disposed of 18.48M sh Series A Preferred Stock — Director, 10% owner
2026-03-02INSIDERBancel Stephane disposed of 1.10M sh Series A Preferred Stock — Director
2026-03-02INSIDERNally Michael disposed of 1.00M sh Series A Preferred Stock — Director, Chief Executive Officer
2026-02-26 00:00 UTCINSIDER17 insider transactions — 2026-02 17 derivative
2026-02-26 00:00 UTCINSIDER17 insider transactions — 2026-02 17 derivative
2026-02-26INSIDERNally Michael acquired 844.6k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage